Intensified postgrafting immunosuppression failed to assure long-term engraftment of dog leukocyte antigen-identical canine marrow grafts after 1 gray total body irradiation.

Transplantation
Mohamed SorrorR Storb

Abstract

Late graft rejection after conditioning with 1 Gy of total body irradiation (TBI) was consistently seen in historical dogs given two postgrafting immunosuppressive drugs. Here, 16 dogs were given four different three-drug combinations of cyclosporine, mycophenolate mofetil, sirolimus, or methotrexate after 1 Gy TBI and dog leukocyte antigen-identical marrow grafts. In addition, we assessed the effects of TBI doses of 0.5, 1.0, 2.0, or 3.0 Gy, respectively, on immune functions in six dogs not given marrow grafts. All dogs showed initial engraftment, 13 rejected, and three had sustained grafts beyond 26 weeks. The dogs with durable grafts had received greater median numbers of nucleated marrow cells compared with the 13 dogs that rejected their grafts (6.14 vs. 3.6 x 10(8) per kg; P=0.03). In a Cox proportional hazard model, which included data from 16 historical dogs, each increase in transplanted marrow cell numbers by 1 x 10(8) per kg decreased the hazard ratio of rejection by 0.5. Decreasing percents of remaining CD3, CD4, and CD8 cells in peripheral blood and lymph nodes were observed with increasing TBI doses. Further, greater suppressions of B-cell- and T-cell-dependent production of IgM and IgG antibodies in response to s...Continue Reading

References

Nov 1, 1993·Fundamental and Applied Toxicology : Official Journal of the Society of Toxicology·L TempleK L White
Nov 1, 1996·Tissue Antigens·J L WagnerR Storb
Jan 5, 2002·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·J M ZauchaB Torok-Storb
Aug 22, 2003·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·William J HoganRainer Storb
Apr 23, 2005·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Razvan DiaconescuRainer Storb
Jan 24, 2007·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Christoph JochumRainer Storb

❮ Previous
Next ❯

Citations

Oct 9, 2009·Current Opinion in Critical Care·Maureen McCunn, Amy J Reed
Aug 12, 2009·Transplantation·Scott S GravesRainer Storb
Oct 4, 2011·American Journal of Veterinary Research·Masahiko SatoHajime Tsujimoto
May 15, 2013·Expert Opinion on Emerging Drugs·Sophie ServaisFrédéric Baron
Jan 24, 2016·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Sandra LangeChristian Junghanss
Sep 3, 2013·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Scott S GravesRainer Storb
Jun 14, 2014·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Christoph MachkaChristian Junghanss
May 12, 2010·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Won Sik LeeRainer Storb
Mar 23, 2010·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·George E GeorgesRichard A Nash
Jan 12, 2011·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Marco MielcarekRainer Storb
May 10, 2020·Veterinary and Comparative Oncology·Scott S Graves, Rainer Storb

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

© 2022 Meta ULC. All rights reserved